Biotalk

No megadeals, no retreat: China’s average deal fell to $1.7B, but it still holds 58% of global licensing value. In the Asia-focused Episode 39, Geoff Meyerson, CEO of Locust Walk, reviews 2026 Q3 trends across China, Japan, and Korea. Last quarter’s question was whether China’s record deal sizes would hold. They didn’t, but volume did, and that matters more. China: $25B in licensing across 15 deals and a third straight billion-dollar-plus venture quarter. The Hang Seng Biotech Index rebounded 2

M&A has already topped all of 2025, and China still holds 58% of global licensing value. In Episode 38 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2026 Q3 Report: Global Trends in Biopharma Transactions. Licensing: $48B across 41 deals. Value fell 33% from Q2 on just a 5% drop in volume: the story was deal size, as Q2’s megadeals rolled off. Upfronts rebounded to 10% of deal value. M&A: $173B year-to-date, already above full-year 2025, as buyers shifted toward de-risked, approv

During the Asia-focused Episode 37 of Biotalk, Geoff Meyerson, CEO of Locust Walk, reviews key trends from the 2026 Q2 Report: Global Trends in Biopharma Transactions, across China, Japan, and Korea. China: Drove ~60% of first-half global licensing value, with the average deal nearing $3B and anchored by the $15B+ Bristol Myers Squibb–Hengrui collaboration. Venture financing posted a second straight billion-dollar-plus quarter ($1.2B) at a three-year high in deal volume. Japan: The Nikkei hit

During Episode 36 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2026 Q2 Report: Global Trends in Biopharma Transactions, covering capital markets, strategic deals, and regional trends. Market Overview: 2026 Q2 confirmed that 2025’s momentum was durable: strategic activity stayed exceptionally strong, public markets kept reopening, and Europe’s venture market rebounded sharply. China cemented its lead in global licensing while the U.S. dominated M&A and public markets. Strategic T

During the Asia-focused Episode 35 of Biotalk, Geoff Meyerson, CEO of Locust Walk, reviews key 2026 Q1 Report: Global Trends in Biopharma Transactions trends across China, Japan, and Korea. China: Dominated global licensing with 66% of deal value -up from 48% in full-year 2025 -anchored by CSPC–AstraZeneca ($18.5B) and Innovent–Lilly ($8.5B). Venture financing surged to a three-year high of $1.2B across 17 deals, led by Corxel Pharmaceuticals’ $287M oral GLP-1 Series D. Out-licensing remains th

During Episode 34 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2026 Q1 Report: Global Trends in Biopharma Transactions, covering capital markets, strategic deals, and regional trends.  Market Overview: Q1 2026 was defined by continuity rather than reversal. Licensing tied a three-year high, M&A recorded its strongest first quarter ever, and U.S. capital markets reopened meaningfully with the return of biotech IPOs. China’s dominance in global licensing expanded further, while Eur